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Abstract
Background: Does the use of angiotensin-converting en-
zyme inhibitors and angiotensin receptor blockers individ-
ually or as a combination confer a survival benefit in hemo-
dialysis patients? The answer to this question is yet unclear. 
Methods: We performed a case-cohort study using data 
from the Mineral and Bone Disorder Outcomes Study for 
Japanese CKD stage 5D patients (MBD-5D), a 3-year multi-
center prospective case-cohort study, including 8,229 he-
modialysis patients registered from 86 facilities in Japan. All 
patients had secondary hyperparathyroidism, a condition 
defined as a parathyroid hormone level ≥180 pg/mL and/
or receiving vitamin D receptor activators. We compared 
all-cause mortality rates between those receiving ACEI, 
ARB, and their combination and non-users with interaction 
testing. We used marginal structural Poisson regression 
(causal model) to estimate the causal effect and interaction 
adjusted for possible time-dependent confounding. Car-
diovascular mortality was also evaluated. Results: Among 
3,762 randomly sampled subcohort patients, those taking 
ACEI, ARB, and their combination at baseline accounted for 
4.0, 31.6, and 3.8%, respectively. Over 3 years, 1,226 all-
cause and 462 cardiovascular deaths occurred. Compared 
to non-users, ARB-alone users had a lower all-cause mortal-
ity rate (adjusted incident rate ratio [aIRR] 0.62, 95% CI 
0.50–0.76), whereas ACEI-alone users showed a statistically 
similar rate (aIRR 1.01, 95% CI 0.57–1.77). On the contrary, 
combination users had a greater mortality rate (aIRR 2.56, 
95% CI 1.22–5.37), showing significant interaction (p = 
0.03). Analysis for cardiovascular mortality showed similar 
results. Conclusion: Among hemodialysis patients with sec-
ondary hyperparathyroidism, unlike ACEI use, ARB use was 
associated with greater survival than non-use. Conversely, 
combination use was associated with greater mortality. 
Controlled trials are warranted to verify the causality fac-
tors of these associations. © 2017 S. Karger AG, Basel
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Introduction
Hemodialysis patients experience a higher mortality 
rate than the general population [1]. The leading cause of 
this mortality is cardiovascular disease (CVD) [2]. De-
spite the importance of identifying modifiable patient or 
dialysis factors or interventions that improve prognosis 
in these patients, interventions for handling traditional 
cardiovascular risk factors that reduce mortality in the 
general population, as well as hemoglobin normalization, 
modification of dialysis prescription, and mineral metab-
olism have failed to decrease all-cause or cardiovascular 
death in these patients [3–7]. 
Renin-angiotensin system inhibitors (RASIs), angio-
tensin-converting enzyme inhibitors, and angiotensin re-
ceptor blockers are widely used in hemodialysis patients 
[8]. Despite this, few studies have evaluated the impact of 
RASIs on the mortality of these patients. Although sev-
eral randomized control trials (RCTs) showed that RASI 
reduced the incidence of deaths, patient numbers were 
small and the studies used an open-label design [9–12]. 
Similar results were obtained from observational studies, 
but these did not estimate the effect of ACEI and ARB 
separately [13–15] and did not consider the possibility of 
time-dependent confounding: blood pressure (BP) levels 
probably associated with mortality [16] are both affected 
by previous RASI use and influence the future prescrip-
tion of RASI. This time-dependent confounding cannot 
be adjusted appropriately and produces bias if conven-
tional analysis such as time-dependent Cox regression is 
used [17, 18]. Thus, it remains unclear whether ACEI or 
ARB independently confers a survival benefit on hemo-
dialysis patients. In particular, the effect of their com-
bined therapy probably used for better control of BP and 
further cardiovascular protection on mortality versus no 
treatment or their interaction has not been investigated.
Here, we explored the association of ACEI, ARB, and 
their combination with mortality in hemodialysis pa-
tients, with interaction testing. We used marginal struc-
tural models (MSMs) that allow the estimation of causal 
effects and interactions adjusted for baseline and time-
dependent variables, with consideration to possible time-
dependent confounding [18, 19].
Materials and Methods
Data Source and Study Design
The study was conducted under a case-cohort design using data 
from the Mineral and Bone Disorder Outcomes Study for Japanese 
CKD stage 5D patients (MBD-5D), a 3-year prospective multi-
center case-cohort study [20]. MBD-5D recorded clinical out-
comes, including all-cause and cardiovascular mortality, from 
 December 2007 to January 2011 in 8,229 maintenance hemodialy-
sis patients with secondary hyperparathyroidism (SHPT) regis-
tered at 86 facilities in Japan. Participants were followed every 
3 months (from visit 0 at registration to visit 12). Clinical data were 
prospectively updated every 6 months as time-dependent vari-
ables, excluding serum albumin, MBD-related serum markers 
(calcium, phosphorus, intact parathyroid hormone [iPTH]) and 
prescriptions (vitamin D receptor activators, phosphate binder, 
and calcimimetics), which were updated every 3 months. A total 
of 3,276 patients were randomly selected from the whole cohort at 
a sampling rate of 40% (Fig. 1). Subcohort participant data were 
collected prospectively, while data for those outside the subcohort 
were collected retrospectively only when they died. Age, gender, 
and iPTH were collected in all 8,229 participants to clarify 
 eligibility.
Study Population
The study population consisted of hemodialysis patients who 
participated in the MBD-5D. Candidates were all patients in the 
participating facilities who had received hemodialysis for more 
than 3 months as of January, 2008. Of these, patients with an iPTH 
level more than 180 pg/dL, the definition of SHPT in Japan accord-
ing to the 2008 guideline [21], or receiving an intravenous or oral 
vitamin D receptor activator for SHPT treatment, were enrolled 
into the whole cohort.
Outcomes, Exposures, and Covariates
Primary outcome was all-cause mortality. Cardiovascular mor-
tality was also evaluated, defined as death due to heart failure, myo-
cardial infarction, cerebrovascular disease, sudden death, arrhyth-
mia, aortic disease, or other CVD.
Exposure of interest was RASI use. The data were categorized 
into 4 classes: ACEI, ARB, combination, and none. They were han-
dled as time-dependent variables updated every 6 months.
Covariates were collected as baseline-fixed variables (age, 
gender, cause of end-stage kidney disease, vintage of dialysis, 
smoking, and comorbid conditions; online suppl. Table 1; 
for  all  online suppl. material, see www.karger.com/
doi/10.1159/000482013), and time-dependent variables (body 
mass index, and data at the section of dialysis, laboratory data, 
and prescription of drugs; online suppl. Table 1). In Japan, calci-
mimetics became available in January, 2008. For missing covari-
ates, we conducted multiple imputations with IVE ware [22]. 
Each of the 5 imputed data sets was constructed by repeating 10 
iterations of sequential imputation for missing data based on a 
regression model according to the type of variable missing [23], 
and used to compute the final estimates.
Statistical Analysis
The primary analysis estimated the adjusted incidence mor-
tality rate ratio (aIRR) using MSMs (online suppl. method). 
These allow the results for exposure effects obtained in nonran-
domized studies to be interpreted as an estimation of the average 
causal effect of exposure after pseudo-randomization of patients 
to different use of RASI while balancing the distribution of po-
tential time-dependent confounders [18, 19] called causal mod-
els. A marginal structural Poisson regression model with robust 
variance was used to compare the outcomes (visit t) for ACEI, 
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ARB, or their combination use, versus no treatment (visit t-1), 
with an interaction test between ACEI and ARB for mortality 
[24], while controlling for possible time-dependent confound-
ing by covariates (visit t-2) such as time-dependent systolic or 
diastolic BP; these were modeled as sixth-degree polynomials 
that influence both future RASI use and mortality, and might 
also act as intermediates between past RASI use and mortality. 
The models for aIRR estimation included the main effect of 
RASI use and the baseline-fixed variables mentioned above with 
weighting by the stabilized inverse probability of RASI treatment 
weight (SW). The final estimated weights for aIRR estimation also 
took account of censoring weights from the inverse probability of 
loss to follow-up and sampling fraction of the random subcohort 
for SWs [25, 26]. Primary analysis was conducted with standard 
MSMs (i.e., untruncated) to avoid exacerbating the inaccuracy of 
estimations by truncation [27]. 
Sensitivity Analysis
We checked that the distribution of SWs was the mean of the 
one that was required for the correct model specification to con-
duct appropriate weighting, as well as the distribution of the fi-
nally estimated weights to confirm the presence of extremely large 
weights [27, 28]. We also examined the truncation of SWs at 100, 
50, and 10 to assess the influence of large weights on our results 
[29]. Then, to explore the model specification for estimating in-
verse probability weights [27], we first examined the influence of 
a change in the number of pre-dialysis BP categories on the effect 
estimate of exposure. Second, we assessed the influence of the step-
by-step addition of potential confounders to the models in calcu-
lating weights on the effect estimate. 
Secondary Analysis
We compared the mortality of ACEI or ARB users to that of 
combination users, or each other, using the same models as in the 
primary analysis by changing the reference category of RASI. We 
then evaluated the consistency of the association between RASI 
and mortality in the models with longer time-lags among out-
comes (visit t), RASI use (visit t-2), and time-dependent confound-
ers (visit t-3). Further, we calculated aIRR with conventional anal-
ysis of baseline-fixed or time-dependent Poisson regression mod-
els in this population. The same covariates as in the primary 
analysis were used for the models, while the time-dependent vari-
ables were fixed at baseline for the baseline-fixed model.
A 2-sided p < 0.05 indicated statistical significance. Data were 
analyzed with SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Patient Characteristics
The 3,276 patients in the random subcohort had a 
median hemodialysis duration of 8.3 years and diabetes 
mellitus rate of 31.6% (Table 1). Baseline age, gender, 
and iPTH levels were similar to those of other partici-
pants (online suppl. Table 2). Baseline RASI use was 
31.6% for ARB, 4.0% for ACEI, and 3.8% for combina-
tion. Over 3 years, these remained similar at every visit, 
whereas the cumulative proportion of patients who 
changed RASI class once or more increased to 41.2% 
during follow-up (online suppl. Fig. 1). Median pre-di-
alysis systolic and diastolic BP fluctuated between 140 
and 150 or 70 and 80 mm Hg respectively. Compared to 
other RASI users, combination users had higher BP and 
proportion of using antihypertensive drugs and diabetes, 
while they had similar or fewer proportion of other car-
Whole cohort (n = 8,229)
Subcohort (n = 3,276) Outside the subcohort (n = 4,953)
Case (n = 1,226)
Deaths in the subcohort:
506 due to all causes
191 due to cardiovascular
disease 
Deaths outside the subcohort:
720 due to all causes
271 due to cardiovascular diseaseFig. 1. Design of this case-cohort study and 
number of deaths. Of the total of 8,229 par-
ticipants as the whole cohort, 40% were 
randomly sampled as a subcohort. Over 
3 years, clinical data of patients included in 
the colored area were actually collected 
prospectively in subcohort patients and 
retrospectively in cases outside the subco-
hort when they died. 
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diovascular risk factors such as past history of CVD (on-
line suppl. Table 1).
Compared to controls, cases were older and had a 
higher proportion of comorbidity with diabetes, CVD, 
and antiplatelet and anticoagulant drug users (online 
suppl. Table 3). They also had lower pre- and post-
dialytic BP and baseline proportion using antihyper-
tensive drugs such as calcium channel blockers and 
RASI. 
Crude Incidence Rate and Rate Ratio of Deaths
Crude incidence curves over 3 years and rate ratio 
of deaths are shown in online supplemental Figure 2. 
In all, 1,226 patients experienced all-cause death, 506 
in the subcohort and 720 outside it (Fig. 1). The inci-
dence rate of all-cause death was 5.5 events/100 per-
son-years. Of these 1,226 deaths, 462 were due to CVD 
(incidence rate, 2.1 events/100 person-years). Com-
pared to non-users, any of ACEI, ARB, and combina-
tion use had a lower crude all-cause mortality rate. The 
results for cardiovascular mortality were similar, except 
for no significant difference for ACEI and combination 
users.
Association of ACEI, ARB, or Their Combination with 
Mortality 
Figure 2 shows the association of RASI use with mor-
tality, adjusted for time-dependent confounding with 
MSMs. Compared to non-users, ARB users had a lower 
all-cause mortality rate (adjusted incidence rate ratio 
[aIRR] 0.62, 95% CI 0.50–0.76), whereas ACEI users had 
a statistically similar rate (aIRR 1.01, 95% CI 0.57–1.77). 
Conversely, combination users had a greater mortality 
rate (aIRR 2.56, 95% CI 1.22–5.37), showing significant 
interaction (p = 0.03). The results for cardiovascular mor-
tality were similar. ARB users had a lower mortality rate 
(aIRR 0.61, 95% CI 0.44–0.84), whereas ACEI users did 
not (aIRR 0.81, 95% CI 0.37–1.75). Combination users 
had a greater mortality rate (aIRR 2.84, 95% CI 1.62–2.98) 
with significant interaction (p = 0.02). 
Table 1. Baseline characteristics related to blood pressure and antihypertensive treatment in participants enrolled in the subcohort (n = 











Age, years 63 (54–71) 3,276 63 (55–71) 62 (54–68) 62 (54–71) 62 (53–69) 0.09
Gender, female, % 38.5 3,276 41.4 31.3 35.8 22.2 <0.001
Duration of dialysis, years 8.3 (3.7–14.3) 3,273 8.9 (4.1–15.9) 9.6 (4.3–15.5) 6.8 (3.0–11.9) 6.7 (2.9–11.4) <0.001
Diabetes mellitus, % 31.6 3,250 27.3 38.5 37.3 45.2 <0.001
Coronary artery
disease, % 27.7 3,238 28.3 33.9 25.5 30.2 0.13
Cerebrovascular
disease, % 16.3 3,239 15.6 16.3 18.1 12.7 0.22
Pre-dialysis blood
pressure, mm Hg
Systolic 151 (136–166) 3,262 148 (131–164) 155 (140–170) 155 (141–170) 160 (147–176) <0.001
Diastolic 80 (70–88) 3,201 79 (70–87) 80 (72–90) 80 (71–90) 80 (72–90) <0.001
Post-dialysis blood
pressure, mm Hg
Systolic 137 (120–153) 3,110 132 (116–148) 136 (124–150) 145 (129–160) 148 (132–164) <0.001
Diastolic 74 (65–82) 3,030 72 (63–80) 76 (70–84) 77 (70–85) 75 (68–85) <0.001
Ultrafiltration rate, L/h 0.65 (0.48–0.8) 3,272 0.63 (0.48–0.78) 0.69 (0.53–0.85) 0.65 (0.5–0.8) 0.73 (0.53–0.88) <0.001
Calcium channel
blocker, % 43.7 3,276 27.8 67.9 66.1 85.7 <0.001
Beta blocker, % 7.1 3,276 4.8 13.7 9.4 18.3 <0.001
Diuretic, % 13.0 3,276 10.9 14.5 15.7 22.2 <0.001
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; RAS, renin-angiotensin system. For conti-
nuous variables, median and interquartile range (IQR) are shown. Differences were evaluated by the Kruskal-Wallis test for conti-
nuous variables, and by the χ2 test for categorical variables. 
All baseline characteristics used for statistical analysis as covariates were described in online supplemental Table 1.
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Sensitivity Analysis
Distribution of the estimated stabilized inverse prob-
ability of RAS inhibitor treatment weight (SW) showed a 
mean of near-one in all 5 datasets for multiple imputation 
(online suppl. Table 4). Few patients had an extremely 
large weight, even after considering both censoring 
weights and random sampling fraction. Truncation of 
SWs at 100, 50, and 10 did not change the results, except 
that the significant association between combination and 
mortality was lost with truncation at 10 (online suppl. 
Table 5).
When an increasing number of BP categories and the 
method of step-by-step addition of covariates were intro-
duced to explore model construction for estimating SWs 
(online suppl. Table 6, 7), the effect estimate increased to 
maximum in the model that fully included the covariates 
with 6 BP categories, which we therefore adopted. Vari-
ance similarly increased but changed toward the null with 
this adopted model. With 7 BP categories, the effects 
could not be computed. Elimination of variables with 
many missing values at baseline before imputation did 
not change the results. 
Secondary Analysis
Compared with either ACEI or ARB users, combina-
tion users had greater all-cause and cardiovascular mor-
tality rates (Table 2). ACEI users had a statistically similar 
but greater mortality rate than ARB users. The longer 
time-lag association of RASI with mortality showed sim-
ilar results to those of the primary analysis, while the as-
sociation of ARB with cardiovascular mortality was not 
statistically significant (online suppl. Table 8). Conven-
tional analysis and analyses with MSMs differed in this 
study population (online suppl. Table 9). Compared to 
non-users, any class of RASI user trended toward lower 
all-cause and cardiovascular mortality. Of these, ARB us-
ers in all analyses and ACEI or combination users in the 
baseline-fixed analysis for all-cause mortality reached 
statistical significance.
Discussion
We found that ARB use in maintenance hemodialysis 
patients with SHPT was associated with lower all-cause 
mortality, whereas ACEI use was not. Moreover, combi-
nation use was conversely associated with greater mortal-
ity, with significant interaction between ACEI and ARB 
use. Analysis for cardiovascular mortality showed similar 
results. To our knowledge, this is the first study to address 
the effect of combined ACEI and ARB versus no treat-
ment on mortality in a hemodialysis setting, with concur-
rent evaluation of the individual effects of ACEI and ARB 
and their interaction. Thus, our results from MSMs esti-
mating the average causal effect of exposure suggest that 
ARB use may help decrease mortality in hemodialysis pa-
tients with SHPT over ACEI therapy, and that their com-
bination may be conversely detrimental.
Our results are consistent with most previous reports 
in hemodialysis patients. Several RCTs evaluated com-
posite cardiovascular events, including all-cause or car-
diovascular death, and demonstrated that ARB reduced 
these events, whereas ACEI did not [9–11]. Although 
one RCT failed to show a survival benefit of ARB, adher-
ence to ARB use was only 51%, possibly causing misclas-
sification that attenuated the effect of ARB [12]. Obser-
vational studies indicated a significant association of 
RASI treated as a binomial variable with all-cause mor-
tality [13–15]. Only one study assessed the associations 
of ARB and ACEI separately in subgroup analysis, and 
the results again suggested that ARB was beneficial, 
whereas ACEI was not [14]. For combination use, a 
comparative effectiveness study showed an association 
with increased risk of cardiovascular death compared to 
ARB alone, as was showed in this study [30]. In non-
dialysis patients with vascular disease or high-risk diabe-



















p value for interaction:
All-cause mortality, p = 0.03
Cardiovascular mortality, p = 0.02
Fig. 2. Association of ACEI, ARB, and their combination use with 
all-cause and cardiovascular mortality rate. Incidence rate ratios 
and results of interaction tests have been adjusted for possible 
time-dependent confounding using marginal structural Poisson 
regression models. The none category is provided as a reference 
for comparison. Bars denote 95% CIs. ACEI, angiotensin-convert-
ing enzyme inhibitor; ARB, angiotensin receptor blocker.
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verse events without an increase in benefit compared to 
ACEI alone [31].
Meanwhile, inconsistent with our results, a recent 
RCT limited to hemodialysis patients with CHF reported 
that combination use had a lower all-cause mortality rate 
than the use of ACEI alone [32]. No other investigation 
of RASI focused on CHF patients in hemodialysis settings 
has appeared. In non-dialysis patients, however, one 
RCT, which similarly enrolled CHF patients only, showed 
a survival benefit for combination use beyond that of 
ACEI-alone use [33]. Also, ACEI has been shown to re-
duce mortality or composite cardiovascular events not 
only in CHF patients [34] but also in non-CHF patients 
with high vascular risk [35]. These findings suggest that 
ACEI or combination use might benefit CHF patients, 
including dialysis patients. Until our present results can 
be conclusively confirmed, it may be preferable that ACEI 
be precautionarily withheld, and used only in combina-
tion for CHF patients. 
Mechanisms of the differential effects of RASI on mor-
tality have not been determined. A recent study in hemo-
dialysis patients demonstrated that molecular regulation 
of the RAS system was highly distorted by ACEI and ARB, 
both alone and in combination [36]. ARB increased an-
giotensin II (Ang2) and suppressed Ang1–7 to a mini-
mum, whereas ACEI and combination showed similar 
regulation, increasing Ang1–7 and suppressing the others 
(excluding increased Ang1–10 with ACEI). Ang1–7 acti-
vates G protein-coupled MAS receptor as an alternative 
RAS pathway, which might have both beneficial and det-
rimental clinical effects [37, 38]. ACEI also blocks Ang2 
type1 receptor incompletely, because Ang2 is generated 
through an ACE-independent pathway, and is strongly 
removed by dialysis, whereas ARB is not affected. Fur-
ther, ACEI activates the kallikrein-kinin system, which is 
further activated by contact of blood with the dialyzer and 
dialysate [39]; and also promotes the generation of bra-
dykinin, which also has both beneficial and detrimental 
effects [40, 41]. Concerning the detrimental effect of com-
bination use, a recent explanation plausibly suggested 
that this resulted from the activation of a pathway in-
duced by renin and prorenin under dual suppression of 
RAS, through highly efficient generation and activity of 
Ang2, and activation of the intracellular signal transduc-
tion pathway directly involved in tissue damage [42]. 
Thus, these complex interplays between beneficial and 
detrimental effects, when further affected by the unique 
characteristics of hemodialysis, may yield the differential 
effects of RASI in hemodialysis patients, particularly re-
garding the attenuation of the beneficial effects of both 
ACEI alone and in combination with ARB.
One of the strengths of our study is the use of MSMs. 
No previous study was considered for possible time-de-
pendent confounding; therefore, our results are more 
likely to be true than such previous nonrandomized stud-
ies. Crude and conventional analyses in this study popu-
lation were inconsistent with those from MSMs, indicat-
ing that considerable time-dependent confounding is in 
fact present. Exploring the construction of the model as 
sensitivity analysis confirmed that our effect estimate in 
MSMs had high precision and better control of confound-
ing. Truncation of SW did not influence our results, while 
statistical significance in the association of combination 
with mortality disappeared only with truncation at 10. 
This might have been due to insufficient adjustment for 
confounding, because approaching truncation toward 1 
means approaching the state of adjustment for baseline 
variables only [27]. The longer time-lag analyses as sec-
ondary analysis were also consistent with our results. Al-
though the association between ARB and mortality did 
Table 2. Comparative effectiveness among ACEI, ARB, and their combination on all-cause and cardiovascular mortality
RAS inhibitor use
ACEI vs. ARB ACEI + ARB vs. ARB ACEI + ARB vs. ACEI
All-cause mortality 
Crude incidence rate ratio 1.15 (0.78–1.69) 1.12 (0.74–1.68) 0.98 (0.57–1.68)
Adjusted incidence rate ratio 1.63 (0.92–2.91) 4.15 (2.02–8.52) 2.56 (1.04–6.32)
Cardiovascular mortality
Crude incidence rate ratio 1.35 (0.77–2.39) 1.42 (0.81–2.51) 1.05 (0.49–2.24)
Adjusted incidence rate ratio 1.34 (0.60–2.98) 4.70 (2.67–8.25) 3.50 (1.49–8.26)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; RAS, renin-angiotensin system.
Values and 95% CIs calculated using marginal structural Poisson regression models were shown.
ACEI, ARB, Their Combination, and 
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not reach significance, misclassification of RASI use dur-
ing long time-lags may attenuate the association. In fact, 
41.2% of the random subcohort experienced one or more 
changes in RASI class during the study.
This study population was limited to hemodialysis pa-
tients with SHPT. They are likely to have higher cardio-
vascular and mortality risk by exposure to abnormal 
mineral and bone metabolism represented by high iPTH 
levels or their treatments, partially through vascular cal-
cification or fraction [43]. This might increase power to 
estimate the effect of RASI use for mortality in a precise 
manner. Also, Japanese physicians had made efforts to 
control iPTH levels within the target level of 60–180 pg/
mL until recently according to the 2008 guideline [21]. 
Although prevalence in Japan is not known, a nationwide 
annual survey in 2009 reported that those with an iPTH 
level over 180 pg/mL accounted for 32.9%, while oral or 
intravenous vitamin D receptor activator users account-
ed for 38.3 and 26.5% respectively [44]. Hemodialysis pa-
tients with both iPTH levels below 180 pg/mL and no 
vitamin D receptor activator use may show different re-
sults from our study. However, this limitation applies to 
many previous studies conducted in hemodialysis pa-
tients with only hypertension, CHF, or left ventricular 
hypertrophy [9–12, 14]. Our consistency with these pub-
lished studies may support the generalizability of our re-
sults. Second, the small number of ACEI and combina-
tion user might reduce power to estimate their effect pre-
cisely. If a larger number of patients taking ACEI, 
especially those with CHF, were randomly selected to 
study population as representative for target population, 
ACEI use might show significant association with reduc-
tion of mortality. Nonetheless, we believe that our find-
ing of statistical significant difference from such study 
population suggests the association of RASI use with 
mortality and their interaction is robust. Why few par-
ticipants were taking ACEI or combination is unclear. 
Japanese physicians might be affected by hard-to-use 
characteristics of ACEI such as activation of generating 
bradykinin by contacting dialyzer, a side effect of cough, 
or removal by dialysis, and possibly by excessive pharma-
ceutical promotion for beneficial effect of ARB, reported 
by some since-retracted papers. Third, our study design 
might have included residual confounding. Even MSMs 
cannot adjust for unmeasured confounders, such as in-
dications for RASI use, similar to other propensity score 
techniques including the matching. We also had no in-
formation on drug dose. An insufficient dose of ACEI 
may prevent the detection of an association with mortal-
ity. Further, we did not collect data on side effects of 
RASI such as serum potassium levels to be detected for 
their abnormal elevation and intradialytic hypotension; 
because these affect future use of RASI, they might be 
important time-dependent confounders. Finally, sub-
group analysis was not achieved because marginal struc-
tural analysis did not converge, likely due to the small 
number of patients following stratification. 
In conclusion, among hemodialysis patients with 
SHPT, ARB use was associated with greater survival than 
non-use, whereas ACEI use was not. Combination use 
was conversely associated with greater mortality, show-
ing significant interaction. These inconsistent effects of 
RASI reinforce the importance of clearly differentiated 
use of ACEI, ARB, and their combination in clinical prac-
tice, despite their categorization as RASIs. Controlled tri-
als are warranted to verify the causality of these 
 associations.
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